A Phase II Study of Erlotinib and modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients with Unresectable or Metastatic Adenocarcinoma of Esophagus and Gastric Cardia.

• IRB# 07-12-010
• For more information contact:
  • Zev Wainberg, MD or
  • Vivian Nguyen
  • 310-794-5463